About Ole Frølich

This author has not yet filled in any details.
So far Ole Frølich has created 29 blog entries.

Pharming Reports On Financial Results For Q1 2015

2017-05-31T19:25:13+02:00April 30, 2015|HAEi News|

Pharming Group N.V. has published its (unaudited) financial report for Q1 2015 ended 31 March 2015. From the financial highlights: Ruconest sales in the US amounted to 0.6 million EUR and sales by Sobi in the EU amounted to 0.4 million EUR. Alongside Pharming realised initial direct sales in Austria, Germany and the Netherlands. Product [...]

Dyax Corp. Announces First Quarter 2015 Financial Results

2017-05-31T19:25:13+02:00April 29, 2015|HAEi News|

Dyax Corp. has announced financial results for the first quarter ended March 31, 2015. Recent highlights include: Reported positive safety, pharmacokinetic, biomarker and proof-of-concept efficacy results from the Phase 1b study of DX-2930 in HAE patients; Receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for the investigation of DX-2930 for [...]

New and Convenient Vial Size of Berinert Accepted by Several European Health Authorities

2015-05-14T16:27:14+02:00April 27, 2015|HAEi News|

Several European health authorities have completed the assessment of a new, low-volume presentation size for the existing indications of Berinert, a human plasma-derived, pasteurized, and nanofiltered C1-esterase inhibitor (C1-INH) concentrate from CSL Behring. It is indicated for the treatment and pre-procedure prevention of acute episodes of HAE type I and II. "This new vial size [...]

Dyax Announces Positive Results from Phase 1b Clinical Trial of DX-2930

2017-05-31T19:25:13+02:00March 31, 2015|HAEi News|

Dyax Corp. has announced positive safety, pharmacokinetic, biomarker, and efficacy results from the Phase 1b clinical study of their investigational product, DX-2930. Discovered by Dyax, DX-2930 is a fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of HAE attacks. The ongoing Phase 1b study is a multi-center, randomized, double-blind, placebo-controlled, [...]

New hae day :-) website

2017-05-31T19:25:13+02:00March 27, 2015|HAEi News|

Today HAEi has launched a new hae day :-) website - a forum dedicated to the global HAE awareness day. Among many other things the website contains a number of case stories, shared by patients in order to help raise awareness of the effects of HAE on the everyday lives of people around the world. [...]

Nominations to Pharming’s Board Of Supervisory Directors

2015-04-07T13:18:02+02:00March 19, 2015|HAEi News|

Pharming Group N.V. has nominated Paul Jai Sekhri and Jan Hendrik Egberts as members of the Board of Supervisory Directors. The nominations will be subject to shareholders’ approval at the upcoming Annual General Meeting of Shareholders, which will take place on 30 April 2015. Mr. Sekhri (1958) has over 28 years of operational experience in [...]

Go to Top